Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00639782




Registration number
NCT00639782
Ethics application status
Date submitted
16/02/2008
Date registered
20/03/2008
Date last updated
25/05/2021

Titles & IDs
Public title
Prospective Randomized On-X Versus SJM Evaluation Trial
Scientific title
Thromboembolic Related Complications in a Randomized Trial of Previous and Current Generation Mechanical Valve Prostheses
Secondary ID [1] 0 0
ONXSJM1
Universal Trial Number (UTN)
Trial acronym
PROSE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Heart Valve Disease 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - On-X Heart valve replacement
Treatment: Devices - SJM Heart valve replacement

Active comparator: ONX - On-X heart Valve Replacement

Active comparator: SJM - SJM heart valve replacement


Treatment: Devices: On-X Heart valve replacement
On-X Heart valve replacement

Treatment: Devices: SJM Heart valve replacement
SJM Heart valve replacement
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Thromboembolisms
Timepoint [1] 0 0
5 years

Eligibility
Key inclusion criteria
1. The patient requires an isolated mitral or isolated aortic valve replacement. (Patients undergoing coronary artery bypass and / or concomitant repair of mitral or tricuspid valves are eligible.)
2. The patient is a candidate for receipt of a mechanical heart valve.
3. The patient (or legal guardian) has signed a study-specific informed consent form agreeing to the randomization, data collection and follow-up requirements.
4. The patient can be having a re-operative procedure, so long as the previous prosthetic valve is explanted and the patient does not become a double valve implantation patient.
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. The patient is not a candidate to receive a mechanical heart valve.
2. The patient already has a prosthetic valve other than the valve(s) being replaced at this time.
3. The patient requires a tricuspid valve replacement.
4. The patient is enrolled in another investigative study or trial.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/07/2003
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/05/2021
Sample size
Target
Accrual to date
Final
857
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Sydney
Recruitment postcode(s) [1] 0 0
2000 - Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Hawaii
Country [3] 0 0
United States of America
State/province [3] 0 0
Missouri
Country [4] 0 0
United States of America
State/province [4] 0 0
New Jersey
Country [5] 0 0
United States of America
State/province [5] 0 0
Pennsylvania
Country [6] 0 0
United States of America
State/province [6] 0 0
Virginia
Country [7] 0 0
Canada
State/province [7] 0 0
British Columbia
Country [8] 0 0
Canada
State/province [8] 0 0
New Brunswick
Country [9] 0 0
Canada
State/province [9] 0 0
Quebec
Country [10] 0 0
Germany
State/province [10] 0 0
Freiburg
Country [11] 0 0
Germany
State/province [11] 0 0
Jena
Country [12] 0 0
Germany
State/province [12] 0 0
Tübingen
Country [13] 0 0
India
State/province [13] 0 0
Gujarat
Country [14] 0 0
India
State/province [14] 0 0
Karnataka
Country [15] 0 0
India
State/province [15] 0 0
Punjab
Country [16] 0 0
India
State/province [16] 0 0
Tamil Nadu
Country [17] 0 0
India
State/province [17] 0 0
Uttar Pradesh
Country [18] 0 0
Netherlands
State/province [18] 0 0
Rotterdam
Country [19] 0 0
Norway
State/province [19] 0 0
Bergen
Country [20] 0 0
South Africa
State/province [20] 0 0
Cape Town
Country [21] 0 0
Sweden
State/province [21] 0 0
Gothenburg

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
On-X Life Technologies, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The study hypothesizes that rate of thromboembolic complications of the On-X prosthesis is reduced as compared to the SJM prosthesis.
Trial website
https://clinicaltrials.gov/study/NCT00639782
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Eric Jamieson, MD
Address 0 0
Vancouver Coastal Health Research Institute
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00639782